FDA approves Pfizer's Hympavzi for hemophilia A/B prophylaxis, first non-factor weekly treatment.

The FDA has approved Pfizer's Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent bleeding in patients aged 12 and older with hemophilia A or B lacking specific inhibitors. This marks the first non-factor, once-weekly treatment for hemophilia B. Administered via an auto-injector, Hympavzi works by reducing tissue factor pathway inhibitor levels, leading to increased thrombin for improved clotting. The approval is based on a study with 116 participants.

October 11, 2024
19 Articles